Item 2.02 Results of Operations and Financial Condition.
On November 14, 2022, Alaunos Therapeutics, Inc. (the “Company”) issued a press
release announcing its financial condition and results of operations for the
three and nine months ended September 30, 2022. A copy of the press release is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On November 14, 2022, the Company presented slides with a business update. A
copy of the presentation is furnished as Exhibit 99.2 to this Current Report on
The information contained in Items 2.02 and 7.01, including Exhibits 99.1 and
99.2, are being “furnished” and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liability of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The
information contained in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2,
shall not be incorporated by reference into any registration statement or other
document pursuant to the Securities Act or into any filing or other document
pursuant to the Exchange Act, except as otherwise expressly stated in any such
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press Release of Alaunos Therapeutics, Inc., dated November 14, 2022. 99.2 Presentation of Alaunos Therapeutics, Inc., dated November 14, 2022. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
© Edgar Online, source Glimpses